AstraZeneca Says Dato-DXd Meets Dual Primary Endpoint Of PFS In Phase III Trial In Lung Cancer
3/7 08:26
(RTTNews) - British drug major AstraZeneca plc (AZN, AZN.L) announced Monday positive high-level results from the TROPION-Lung01 Phase III trial of datopotamab deruxtecan (Dato-DXd) in patients with advanced non-small cell lung cancer....